There are few studies on LAG-3 expression in DLBCL, and further research to determine whether it can be an effective therapeutic target for DLBCL and improve PD-1 inhibitor resistance is warranted. The gene discussed is PDCD1; the disease is diffuse large B-cell lymphoma.